跳至主要内容
临床试验/NCT01885091
NCT01885091已完成4 期

Kinerase® Interactive Skin-care Study: A Multicentre, Phase IV, Single-arm, Open-label Trial to Evaluate the Efficacy and Safety of Kinetin, N6-furfuryladenine, 0.1% for Treatment of Cutaneous Facial Photodamage

Menarini (Thailand) Limited2 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2012年12月1日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
100
试验地点
2
主要终点
To assess the physician's evaluation and patient's self-evaluation at 8 weeks.

研究概览

简要总结

The purpose of the K.I.S.S. study is to evaluate the efficacy of Kinerase® Cream (Kinetin 0.1%) in Thai patients, on the basis of the severity and clinical signs of facial photodamage.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
35 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female subjects older than 35 years of age and less than 65 years of age.
  • Subjects with mild, moderate or severe facial photodamage as assessed by a 10-point scale.
  • Subjects willing to sign an informed consent and adhere to all protocol requirements.

排除标准

  • Male and female subjects with suspected porphyria, systemic or cutaneous erythematosus lupus, or any other photosensitizing disorder or drug-induced photosensitization.
  • Subjects with chronic or recurring skin disease or disorder.
  • Subjects with any active infectious skin disorder (Herpes simplex, molluscum contagiosum, and facial warts).
  • Subjects with skin cancer of the facial tissues.
  • Subjects who have received any laser/ intense pulsed light (IPL) / chemical peel in the 2 months preceding the screening visit.
  • Subjects with a history of topical and/or oral isotretinoin use, 6 months prior to the screening visit.
  • Subjects who have been on topical Retin-A or Renova in the 2 months prior to the screening visit.
  • Subjects who have used topical alpha-hydroxy acid skin care products in the month preceding the screening visit.
  • Subjects currently on any anti-aging products and who wish to continue use of their products.
  • Subjects requiring concurrent treatment that would interfere with the study assessments.
  • Pregnant or lactating female subjects.

结局指标

主要结局

To assess the physician's evaluation and patient's self-evaluation at 8 weeks.

时间窗: 8 weeks

To assess the physician's evaluation and patient's self-evaluation at 12 weeks.

时间窗: 12 weeks

To assess the physician's evaluation and patient's self-evaluation at 4 weeks.

时间窗: 4 weeks

次要结局

未报告次要终点

研究者

发起方
Menarini (Thailand) Limited
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验